Immune mediated lung injury in COVID-19

COVID-19 中免疫介导的肺损伤

基本信息

  • 批准号:
    10367945
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-04-01 至 2023-03-31
  • 项目状态:
    已结题

项目摘要

SARS-CoV-2 and the disease it causes (COVID-19) has emerged as a major global public health threat in the span of a few months. In particular, SARS-CoV-2 adds to the present number of acute respiratory infections, including influenza and bacterial pneumonia, which are endangering the health of our veterans and aging population. In particular, severe COVID-19 disease is characterized by severe lung injury, which results in severely impaired oxygen delivery and ultimately multiple organ failure and death. Our ongoing research has focused on a population of white blood cells called neutrophils, which are the most abundant white blood cell in our body and which have been shown to be a pivotal immune cell that contributes greatly to lung injury. However, our current medical knowledge is inadequate for understanding what neutrophils do in the context of viral infection. Although neutrophils are critical for eliminating many types of infections, they are believed to be a major contributor to the development of lung injury, and how to balance their beneficial activities with their harmful functions is poorly understood. Therefore, a better understanding of how neutrophils behavior and phenotype are altered during severe SARS-CoV-2 and other viral infections would aid in developing novel therapies to improve their antimicrobial functions, while limiting their injurious effects. The research we propose in this grant will examine how well neutrophils eliminate SARS-CoV-2 viruses, or if they are an excessively activated population of immune cells recruited to the lung whose harmful activities outweighs their benefits. We also will test an exciting new treatment approach developed by our collaborator at UCLA to see if this can block the damaging effects of neutrophils on lung cells, while blocking viral replication. The results of this 2-year project will provide insights into the beneficial versus harmful contributions of neutrophils in the development of severe COVID-19 disease, and potentially identify new therapies to benefit veterans and other vulnerable patients.
SARS-CoV-2及其引起的疾病(COVID-19)已成为全球公众关注的主要问题, 几个月内的健康威胁。特别是,SARS-CoV-2增加了目前 流感和细菌性肺炎等急性呼吸道感染的数量 危及退伍军人和老龄化人口的健康。特别是,严重的COVID-19 这种疾病的特征是严重的肺损伤,这导致严重的氧气受损 最终导致多器官衰竭和死亡。我们正在进行的研究集中在一个 一群称为中性粒细胞的白色血细胞,是最丰富的白色血细胞 在我们的身体,已被证明是一个关键的免疫细胞,大大有助于 肺损伤然而,我们目前的医学知识不足以理解 嗜中性粒细胞在病毒感染的情况下是这样的。虽然中性粒细胞对于消除 许多类型的感染,他们被认为是一个主要贡献者的发展,肺 伤害,以及如何平衡其有益的活动与有害的功能是很差的 明白因此,更好地了解中性粒细胞的行为和表型是如何 在严重的SARS-CoV-2和其他病毒感染期间改变将有助于开发新的 治疗,以提高其抗微生物功能,同时限制其有害作用。的 我们在这项拨款中提出的研究将检查中性粒细胞如何消除SARS-CoV-2 病毒,或者如果它们是过度激活的免疫细胞群, 他们的行为弊大于利我们还将测试一种令人兴奋的新疗法 我们的合作者在加州大学洛杉矶分校开发的方法,看看这是否可以阻止破坏性的影响, 肺细胞上的中性粒细胞,同时阻断病毒复制。这个为期两年的项目将 提供了对中性粒细胞的有益和有害贡献的见解, 发展严重的COVID-19疾病,并可能发现新的治疗方法, 退伍军人和其他脆弱的病人。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Neutrophils drive pulmonary vascular leakage in MHV-1 infection of susceptible A/J mice.
  • DOI:
    10.3389/fimmu.2022.1089064
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    7.3
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jane C Deng其他文献

Jane C Deng的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jane C Deng', 18)}}的其他基金

Immune mediated lung injury in COVID-19
COVID-19 中免疫介导的肺损伤
  • 批准号:
    10154065
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Neutrophil heterogeneity and function in host defense during pulmonary infection
肺部感染期间中性粒细胞异质性和宿主防御功能
  • 批准号:
    9974284
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Neutrophil heterogeneity and function in host defense during pulmonary infection
肺部感染期间中性粒细胞的异质性和宿主防御功能
  • 批准号:
    10266038
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Neutrophil heterogeneity and function in host defense during pulmonary infection
肺部感染期间中性粒细胞的异质性和宿主防御功能
  • 批准号:
    10645077
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Mechanisms of Impaired Neutrophil Responses in PostInfluenza Bacterial Pneumonia
流感后细菌性肺炎中中性粒细胞反应受损的机制
  • 批准号:
    9272520
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Mechanisms of impaired neutrophil responses in postinfluenza bacterial pneumonia
流感后细菌性肺炎中性粒细胞反应受损的机制
  • 批准号:
    8372229
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Mechanisms of impaired neutrophil responses in postinfluenza bacterial pneumonia
流感后细菌性肺炎中性粒细胞反应受损的机制
  • 批准号:
    8508300
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Mechanisms of impaired neutrophil responses in postinfluenza bacterial pneumonia
流感后细菌性肺炎中性粒细胞反应受损的机制
  • 批准号:
    8677960
  • 财政年份:
    2012
  • 资助金额:
    --
  • 项目类别:
Mechanisms of dysregulated immunity with aging
衰老过程中免疫失调的机制
  • 批准号:
    9975665
  • 财政年份:
    2007
  • 资助金额:
    --
  • 项目类别:
Mechanisms of dysregulated immunity with aging
衰老过程中免疫失调的机制
  • 批准号:
    10385857
  • 财政年份:
    2007
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
  • 批准号:
    10648387
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
  • 批准号:
    10720687
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
  • 批准号:
    10719249
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
  • 批准号:
    10591804
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
  • 批准号:
    10741574
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
  • 批准号:
    23K07651
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
  • 批准号:
    10679944
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
  • 批准号:
    10575258
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
  • 批准号:
    10701207
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Identification of novel phenotypes of acute lung injury using multimodal longitudinal data
使用多模态纵向数据识别急性肺损伤的新表型
  • 批准号:
    MR/Y000404/1
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Fellowship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了